Centessa Pharmaceuticals【0ACX】銘柄情報

Centessa Pharmaceuticals Plc (0ACX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

( - )

買値

0.00

売値

0.00

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

0.00

始値

時刻

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 2,603,355

発行済株式数

154,728,966

配当利回り

PER

-22.32

1 株当たり利益 (EPS)

-1.78

歳入

純利益

-250.64M

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of cen... Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. 詳細を表示

セクター

業界

ウェブサイト

centessa.com

本社

Altrincham, United Kingdom

設立

2026

Centessa Pharmaceuticals Plc is listed in the sector of the ロンドン証券取引所 with ticker 0ACX. The last closing price for Centessa Pharmaceuticals was US$0. Over the last year, Centessa Pharmaceuticals shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Centessa Pharmaceuticals currently has 154,728,966 shares in issue. Centessa Pharmaceuticals has a price to earnings ratio (PE ratio) of -22.32.

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline...

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications ...

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE...

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa...

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 Advancing a broad, potential...

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist;...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 Advancing a broad, potential...

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 Advancing a broad, potential...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

0ACX - Frequently Asked Questions (FAQ)

What is the current Centessa Pharmaceuticals Plc share price?

The current share price of Centessa Pharmaceuticals Plc is US$ 0.00

How many Centessa Pharmaceuticals Plc shares are in issue?

Centessa Pharmaceuticals Plc has 154,728,966 shares in issue

What is the 1 year trading range for Centessa Pharmaceuticals Plc share price?

Centessa Pharmaceuticals Plc has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Centessa Pharmaceuticals Plc?

The price to earnings ratio of Centessa Pharmaceuticals Plc is -22.32

What is the registered address of Centessa Pharmaceuticals Plc?

The registered address for Centessa Pharmaceuticals Plc is 1 Ashley Road, Altrincham, Cheshire, WA14 2DT

What is the Centessa Pharmaceuticals Plc website address?

The website address for Centessa Pharmaceuticals Plc is centessa.com

Golden Cross 5分前

$AABB Loading Zone... Think we found the bottom here

$AABB
https://investorshub.advfn.com/uimage/uploads/2026/6/17/lgedbaabb.png

AABB

Idunno 5分前

Ah. I forgot the F. And I’m not your brother. And your people have a big problem. Ttyl.

NWBO

Little Birdie 1 6分前

This was a cash starved, preclinical, near totally redeemed de-SPAC trading on narrative and a thin float

VRXA

US Market News 8分前

NGL Energy Partners LP Announces Quarterly Cash Distribution for the Class B, Class C, and Class D Preferred UnitsJune 17, 2026 6:30 AM
Business Wire NGL Energy Partners LP (NYSE: NGL) announced today that the Board of Directors of its general partner declared a distribution fo

NGL

US Market News 8分前

Broadridge Joins Anthropic's Project GlasswingJune 17, 2026 6:30 AM
PR Newswire (US) Strategic AI partnership helping secure critical software in the AI era class="legendSpanClass"NEW YORK, class="legendSpanClass"June 17, 2

US Market News 8分前

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All AgesJune 17, 2026 6:45 AM
Business Wire Efficacy and safety are top preferences when selecting

MRK

Stuart_Stardust 11分前

Sign of life, but far from interesting in any aspect. Seriously come on, take yourself seriously!

CNBX

OBAI

Good morning all.

TPTW-EM……!!!!!!!

VuMe Live 😎😎😎

TPTW

theorysuit 15分前

Lmfao I wouldnt expect any less from a paid pump. Go log on as another alias brother

NWBO

misterfishman 17分前

No bro your not the only one i have been here two months and i a tired already.

CNBX

Quick Sand 18分前

Surely some sort of governance was used by the board to approve these bonuses ?
Either way, it’s nothing short of blatant stealing
And shareholders should hold them accountable.

QSEP

misterfishman 20分前

I was two yrs old in 66 back in london england.......dont remember a thing.....well i am not sure if it was a dream or repressed memory the brain is not fully developed at two.

NNRX

ColdDarkHole 20分前

There is no life changing news. Maybe share count changing news when they do the reverse split to bring the share count down from the moon. There is nothing special here. This is a pre-revenue company. Elon Musk is nowhere near this. Tesla is not buying this.

SEII

Idunno 21分前

You got your work cut out for you now! As you might say, LMAO, at you. Get back to work!

NWBO

ColdDarkHole 23分前

The price is 16% of 1 cent. It doesn't get cheaper. I wouldn't buy more shares if it was half that.

SEII

Eman356 24分前

Was part of the fins that included the $100m revenue run rate and details on Pemex and the Panama Canal. They even called out chemist for his charting prowess.

MVNT

PEACHMAN 26分前

I've also been holding and adding DTREFand IFUS

DTREF

ITYS 28分前

THESE are the FACTS that SHAKE our heads:

HOW can MWWC facilitate a definitive agreement with Blagmans company is THERE ISNT ONE?

SURELY one of the supporters can answer this simple concern?
WHY isnt there a Material event filed or anything letting shareholders k

MWWC

Golden Cross 32分前

Loading... Think we found the bottom here

$AABB
https://investorshub.advfn.com/uimage/uploads/2026/6/17/lgedbaabb.png

AABB

US Market News 37分前

NIQ Introduces NIQ Cadence: A Compound AI Operating System for Marketing EffectivenessJune 17, 2026 6:00 AM
Business Wire One system unifies NIQ’s global data, models, and knowledge so marketers move from insight to impact faster, with deeper intelligence, at scale. NIQ

NIQ

CA Market News 37分前

Generation Mining Receives Senior Lender Credit Approval for US$310 Million from EDC, ING Capital, and Société GénéraleJune 17, 2026 6:00 AM
Business Wire Generation Mining Limited (TSX: GENM) (OTCQB: GENMF) (the “Company”) is pleased to announce that Export Development Canada

GENM

US Market News 37分前

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior NotesJune 17, 2026 6:00 AM
Business Wire NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previous

NEO

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Centessa Pharmaceuticals Plc (0ACX)

Centessa Pharmaceuticals Plc (0ACX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Centessa Pharmaceuticals Plc について

0ACX 最新ニュース

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

0ACX - Frequently Asked Questions (FAQ)

0ACX 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Centessa Pharmaceuticals Plc (0ACX)

Centessa Pharmaceuticals Plc (0ACX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Centessa Pharmaceuticals Plc について

0ACX 最新ニュース

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

0ACX - Frequently Asked Questions (FAQ)

0ACX 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR